The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary

Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial

(2018) Pascal Vranckx et al.   AMERICAN HEART JOURNAL

Clinical Outcomes and History of Fall in Patients with Atrial Fibrillation Treated with Oral Anticoagulation: Insights From the ARISTOTLE Trial

(2018) Meena P. Rao et al.   AMERICAN JOURNAL OF MEDICINE

Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference

(2018) Dipak Kotecha et al.   EUROPACE

The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation

(2018) Jan Steffel et al.   EUROPEAN HEART JOURNAL

Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism

(2018) Gary E. Raskob et al.   NEW ENGLAND JOURNAL OF MEDICINE

Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging

(2018) Gregory W. Albers et al.   NEW ENGLAND JOURNAL OF MEDICINE

Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct

(2018) Raul G. Nogueira et al.   NEW ENGLAND JOURNAL OF MEDICINE

2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association

(2018) William J. Powers et al.   STROKE

Shifting to a non-vitamin K antagonist oral anticoagulation agent from vitamin K antagonist in atrial fibrillation

(2017) Emil L Fosbøl et al.   EUROPACE

Impact of pre-admission oral anticoagulation on ischaemic stroke volume, lesion pattern, and frequency of intracranial arterial occlusion in patients with atrial fibrillation

(2017) Joanna Dietzel et al.   EUROPACE

Frailty syndrome: an emerging clinical problem in the everyday management of clinical arrhythmias. The results of the European Heart Rhythm Association survey

(2017) Stefano Fumagalli et al.   EUROPACE

Challenges in comparing the non-vitamin K antagonist oral anticoagulants for atrial fibrillation-related stroke prevention

(2017) A John Camm et al.   EUROPACE

Percutaneous left atrial appendage occlusion in atrial fibrillation patients with a contraindication to oral anticoagulation: a focused review

(2017) Marin Nishimura et al.   EUROPACE

Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients undergoing elective cardioversion

(2017) Saga Itäinen et al.   EUROPACE

Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA Registry

(2017) Martín Ruiz Ortiz et al.   EUROPACE

Cardioversion of atrial fibrillation in a real-world setting: non-vitamin K antagonist oral anticoagulants ensure a fast and safe strategy compared to warfarin

(2017) Anne Sofie Frederiksen et al.   EUROPACE

2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary

(2017) Hugh Calkins et al.   EUROPACE

Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE)

(2017) Gregory Y H Lip et al.   EUROPACE

Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation

(2017) Fernando Dominguez et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Direct oral anti-coagulants compared with vitamin-K inhibitors and low-molecular-weight-heparin for the prevention of venous thromboembolism in patients with cancer: A meta-analysis study

(2017) Natale Daniele Brunetti et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany – A national case collection

(2017) Pawel Kermer et al.   International Journal of Stroke

Comparisons of Interventions for Preventing Falls in Older Adults

(2017) Andrea C. Tricco et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Non–Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease

(2017) Giulia Renda et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial

(2017) Raffaele De Caterina et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants

(2017) Gordon F. Tomaselli et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians

(2017) J. Douxfils et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation

(2017) Eleni Korompoki et al.   NEUROLOGY

Triple Therapy for Atrial Fibrillation after PCI

(2017) Jonathan P. Piccini et al.   NEW ENGLAND JOURNAL OF MEDICINE

Idarucizumab for Dabigatran Reversal — Full Cohort Analysis

(2017) Charles V. Pollack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation

(2017) Hugh Calkins et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale

(2017) Alex Spyropoulos et al.   THROMBOSIS AND HAEMOSTASIS

Effects of Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta‐Analysis

(2017) Kuo‐Li Pan et al.   Journal of the American Heart Association

Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non–Vitamin‐K Oral Anticoagulants (RAF‐NOACs) Study

(2017) Maurizio Paciaroni et al.   Journal of the American Heart Association

Management of direct oral anticoagulants in patients undergoing elective surgeries and invasive procedures: Updated guidelines from the French Working Group on Perioperative Hemostasis (GIHP) – September 2015

(2017) Pierre Albaladejo et al.   Anaesthesia Critical Care & Pain Medicine

Intravenous Thrombolysis in Patients with Stroke Taking Rivaroxaban Using Drug Specific Plasma Levels: Experience with a Standard Operation Procedure in Clinical Practice

(2017) David J. Seiffge et al.   Journal of Stroke

On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With WarfarinClinical Perspective

(2016) Christopher B. Fordyce et al.   CIRCULATION

Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 TrialClinical Perspective

(2016) Erin A. Bohula et al.   CIRCULATION

Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart DiseaseClinical Perspective

(2016) Michael D. Ezekowitz et al.   CIRCULATION

Interactions between non-vitamin K oral anticoagulants and antiepileptic drugs

(2016) Claudia Stöllberger et al.   EPILEPSY RESEARCH

Perioperative management of antithrombotic treatment during implantation or revision of cardiac implantable electronic devices: the European Snapshot Survey on Procedural Routines for Electronic Device Implantation (ESS-PREDI)

(2016) Jean-Claude Deharo et al.   EUROPACE

Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort

(2016) Menno V. Huisman et al.   EUROPACE

Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation

(2016) Luigi Di Biase et al.   EUROPACE

The ‘obesity paradox’ in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial

(2016) Roopinder K. Sandhu et al.   EUROPEAN HEART JOURNAL

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

(2016) Paulus Kirchhof et al.   EUROPEAN HEART JOURNAL

Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease

(2016) Peter A. Noseworthy et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Measuring non-vitamin K antagonist oral anticoagulant levels: When is it appropriate and which methods should be used?

(2016) Ludovic Drouet et al.   International Journal of Stroke

Time to Treatment With Endovascular Thrombectomy and Outcomes From Ischemic Stroke: A Meta-analysis

(2016) Jeffrey L. Saver et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Stroke and Bleeding Risks in NOAC- and Warfarin-Treated Patients With Hypertrophic Cardiomyopathy and Atrial Fibrillation

(2016) Peter A. Noseworthy et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling

(2016) Jan Steffel et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Obesity and risk of bleeding: the SMART study.

(2016) S. K. Braekkan et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores

(2016) G. Y. H. Lip et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH

(2016) J. H. Levy et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH

(2016) K. Martin et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment

(2016) Allison E. Burnett et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial

(2016) Andreas Goette et al.   LANCET

The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study

(2016) Ziad Hijazi et al.   LANCET

Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors

(2016) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety of Endovascular Thrombectomy in Patients Receiving Non–Vitamin K Antagonist Oral Anticoagulants

(2016) Jan C. Purrucker et al.   STROKE

Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF–TIMI 48 Trial

(2016) Eri Toda Kato et al.   Journal of the American Heart Association

Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF‐TIMI48 Trial

(2016) Haiyan Xu et al.   Journal of the American Heart Association

Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time

(2016) Ziad Hijazi et al.   JAMA Cardiology

Intracranial Hemorrhage and Subsequent Ischemic Stroke in Patients With Atrial Fibrillation

(2015) Peter Brønnum Nielsen et al.   CHEST

Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart DiseaseCLINICAL PERSPECTIVE

(2015) Alvaro Avezum et al.   CIRCULATION

Non-vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: the concept for a trial

(2015) Raffaele De Caterina et al.   EUROPACE

Non-vitamin K antagonist oral anticoagulants (NOAC): considerations on once- vs. twice-daily regimens and their potential impact on medication adherence

(2015) Hein Heidbuchel et al.   EUROPACE

Is one month treatment with dabigatran before cardioversion of atrial fibrillation sufficient to prevent thromboembolism?: Table 1

(2015) Anna-Karin Johansson et al.   EUROPACE

Non-vitamin K oral anticoagulants in ‘valvular’ atrial fibrillation: a call for action

(2015) Jan Steffel et al.   EUROPACE

Oral anticoagulant therapy for stroke prevention in patients with atrial fibrillation undergoing ablation: results from the First European Snapshot Survey on Procedural Routines for Atrial Fibrillation Ablation (ESS-PRAFA)

(2015) T. S. Potpara et al.   EUROPACE

Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS)

(2015) Christian Sticherling et al.   EUROPACE

Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation

(2015) Hein Heidbuchel et al.   EUROPACE

Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation

(2015) Riccardo Cappato et al.   EUROPEAN HEART JOURNAL

Mechanical thrombectomy in acute ischemic stroke: Consensus statement by ESO-Karolinska Stroke Update 2014/2015, supported by ESO, ESMINT, ESNR and EAN

(2015) Nils Wahlgren et al.   International Journal of Stroke

Anticoagulant Reversal, Blood Pressure Levels, and Anticoagulant Resumption in Patients With Anticoagulation-Related Intracerebral Hemorrhage

(2015) Joji B. Kuramatsu et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Early Recurrence and Cerebral Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation

(2015) Maurizio Paciaroni et al.   STROKE

Guidelines for the Management of Spontaneous Intracerebral Hemorrhage

(2015) J. Claude Hemphill et al.   STROKE

Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants

(2015) Florian Posch et al.   THROMBOSIS RESEARCH

Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry

(2014) J. Beyer-Westendorf et al.   BLOOD

2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation

(2014) Craig T. January et al.   CIRCULATION

Stratifying the Risks of Oral Anticoagulation in Patients With Liver Disease

(2014) Lydia M. Efird et al.  

Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation

(2014) Riccardo Cappato et al.   EUROPEAN HEART JOURNAL

Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial

(2014) Günter Breithardt et al.   EUROPEAN HEART JOURNAL

Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry

(2014) J. Beyer-Westendorf et al.   EUROPEAN HEART JOURNAL

Edoxaban population pharmacokinetics and exposure–response analysis in patients with non-valvular atrial fibrillation

(2014) Ophelia Q. P. Yin et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Rivaroxaban presents a better pharmacokinetic profile than dabigatran in an obese non-diabetic stroke patient

(2014) Apostolos Safouris et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Use of PER977 to Reverse the Anticoagulant Effect of Edoxaban

(2014) Jack E. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intracranial Hemorrhage and Novel Anticoagulants for Atrial Fibrillation: What Have We Learned?

(2014) Graeme J. Hankey   Current Cardiology Reports

Expert consensus of the French Society of Geriatrics and Gerontology and the French Society of Cardiology on the management of atrial fibrillation in elderly people

(2013) Olivier Hanon et al.   Archives of Cardiovascular Diseases

Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects

(2013) Vijay V. Upreti et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor

(2013) Dagmar Kubitza et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation

(2013) Ziad Hijazi et al.   CIRCULATION

European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation

(2013) Hein Heidbuchel et al.   EUROPACE

Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial

(2013) J. H. Alexander et al.   EUROPEAN HEART JOURNAL

Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials

(2013) Christian T Ruff et al.   LANCET

Ischemic Stroke in an Obese Patient Receiving Dabigatran

(2013) Lorenz Breuer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Edoxaban versus Warfarin in Patients with Atrial Fibrillation

(2013) Robert P. Giugliano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Apixaban for the Treatment of Acute Venous Thromboembolism

(2013) Giancarlo Agnelli et al.   NEW ENGLAND JOURNAL OF MEDICINE

New Oral Anticoagulants and the Cancer Patient

(2013) N. J. Short et al.   ONCOLOGIST

Preventing Stroke in Patients With Chronic Kidney Disease and Atrial Fibrillation

(2013) Holger Reinecke et al.   STROKE

Atrial Fibrillation and Acute Myocardial Infarction: Antithrombotic Therapy and Outcomes

(2012) Renato D. Lopes et al.   AMERICAN JOURNAL OF MEDICINE

Variation in Warfarin Dose Adjustment Practice Is Responsible for Differences in the Quality of Anticoagulation Control Between Centers and Countries

(2012) Harriette G.C. Van Spall et al.   CIRCULATION

Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial

(2012) Antonio L. Dans et al.   CIRCULATION

Apixaban in renal insufficiency: successful navigation between the Scylla and Charybdis

(2012) J. Steffel et al.   EUROPEAN HEART JOURNAL

Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial

(2012) Stefan H. Hohnloser et al.   EUROPEAN HEART JOURNAL

Impact of dabigatran on a large panel of routine or specific coagulation assays

(2012) Séverine Robert et al.   THROMBOSIS AND HAEMOSTASIS

Assessment of the impact of rivaroxaban on coagulation assays: Laboratory recommendations for the monitoring of rivaroxaban and review of the literature

(2012) Jonathan Douxfils et al.   THROMBOSIS RESEARCH

Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation

(2011) John W. Eikelboom et al.   CIRCULATION

Rivaroxaban

(2011) Wolfgang Mueck et al.   CLINICAL PHARMACOKINETICS

Menstrual problems and contraception in women of reproductive age receiving oral anticoagulation

(2011) Farah Yasmine Huq et al.   CONTRACEPTION

Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment

(2011) K. A. A. Fox et al.   EUROPEAN HEART JOURNAL

Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial

(2011) K.-H. LIESENFELD et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)

(2011) Charles A. Herzog et al.   KIDNEY INTERNATIONAL

Apixaban versus Warfarin in Patients with Atrial Fibrillation

(2011) Christopher B. Granger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

(2011) Manesh R. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial

(2010) Lars Wallentin et al.   LANCET

Pharmacokinetics and Pharmacodynamics of the Direct Oral Thrombin Inhibitor Dabigatran in Healthy Elderly Subjects

(2009) Joachim Stangier et al.   CLINICAL PHARMACOKINETICS

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effective Exercise for the Prevention of Falls: A Systematic Review and Meta-Analysis

(2008) Catherine Sherrington et al.   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

Dilemmas in the Management of Atrial Fibrillation in Chronic Kidney Disease

(2008) H. Reinecke et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY